Document Detail

Update on reproductive safety of current and emerging disease-modifying therapies for multiple sclerosis.
MedLine Citation:
PMID:  23319073     Owner:  NLM     Status:  Publisher    
For physicians who care for patients with multiple sclerosis (MS), the use of disease-modifying therapies (DMTs) during the conception period and pregnancy raises important safety considerations. All DMTs have potential adverse effects on fertility, pregnancy outcomes, and breastfed infants. Although physicians are reluctant to prescribe DMTs to MS patients who are contemplating having a family or are already pregnant, treatment can be warranted in those who have active disease. This review assembles the most current information on the reproductive safety of approved and emerging DMTs drawn from the literature and information supplied by the manufacturers.
Bruce Ac Cree
Related Documents :
24865483 - Associations between 25-hydroxyvitamin d levels and pregnancy outcomes: a prospective o...
23571133 - Tachysystole in term labor: incidence, risk factors, outcomes, and effect on fetal hear...
6307553 - Angiotensin-converting enzyme and the renin-angiotensin system in normotensive primigra...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2013-1-14
Journal Detail:
Title:  Multiple sclerosis (Houndmills, Basingstoke, England)     Volume:  -     ISSN:  1477-0970     ISO Abbreviation:  Mult. Scler.     Publication Date:  2013 Jan 
Date Detail:
Created Date:  2013-1-15     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9509185     Medline TA:  Mult Scler     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Department of Neurology, UCSF Medical Center, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Early brain pseudoatrophy while on natalizumab therapy is due to white matter volume changes.
Next Document:  Prognostic value of tumor size in gastric cancer: an analysis of 2,379 patients.